How does the Stelara patent loss affect JNJ?

The patent loss allows biosimilar competitors to enter, significantly reducing Stelara revenue.

Is JNJ stock a buy right now?

The article does not provide a buy or sell recommendation but notes the balance between growth opportunities and Stelara patent loss challenges.

J&J Stock Gains Nearly 12% YTD: Buy, Sell or Hold Now?

Q: What drove JNJ stock up 12% YTD?

The stock rose due to strong growth in oncology drugs and the MedTech segment, along with pipeline progress.

Johnson & Johnson (JNJ) stock has risen nearly 12% year-to-date, supported by robust oncology drug sales, MedTech demand, and pipeline progress, offsetting Stelara patent-loss headwinds. This article analyzes whether investors should buy, sell, or hold.

Johnson & Johnson (JNJ) shares have gained approximately 12% year-to-date, driven by strong growth in oncology drugs and the MedTech segment, along with promising pipeline developments. This performance comes despite the pressure from the Stelara patent loss, which was a major revenue contributor.

Stock Performance

JNJ has outperformed some peers in the healthcare sector since the start of the year. The uptick reflects investor confidence in the company's strategy to offset Stelara's revenue decline through innovation in new areas.

Growth Drivers

Oncology

JNJ's oncology portfolio, including drugs like Darzalex and Imbruvica, has shown significant growth, boosting overall revenue.

MedTech

The MedTech segment has experienced rising demand for surgical and cardiovascular devices, supporting the company's top line.

Pipeline

A robust pipeline of drug candidates awaiting approval promises future revenue streams.

Challenges

Stelara Patent Loss

The expiration of Stelara's patent allows biosimilar competitors to enter the market, which will negatively impact revenue.

What This Means for Investors

JNJ stock presents a balance of opportunities and challenges. Long-term investors seeking stability may find JNJ attractive due to its diversified business and innovation strength. However, the impact of Stelara's patent loss on future earnings should be closely monitored.